BR112012030689A2 - cristal de derivado de tienopirimidina - Google Patents

cristal de derivado de tienopirimidina

Info

Publication number
BR112012030689A2
BR112012030689A2 BR112012030689A BR112012030689A BR112012030689A2 BR 112012030689 A2 BR112012030689 A2 BR 112012030689A2 BR 112012030689 A BR112012030689 A BR 112012030689A BR 112012030689 A BR112012030689 A BR 112012030689A BR 112012030689 A2 BR112012030689 A2 BR 112012030689A2
Authority
BR
Brazil
Prior art keywords
derivative crystal
thienopyrimidine derivative
crystals
thienopyrimidine
heating
Prior art date
Application number
BR112012030689A
Other languages
English (en)
Other versions
BR112012030689B1 (pt
Inventor
Hiroyuki Hayashi
Koichi Miyazaki
Takayoshi Nakagawa
Original Assignee
Aska Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharm Co Ltd filed Critical Aska Pharm Co Ltd
Publication of BR112012030689A2 publication Critical patent/BR112012030689A2/pt
Publication of BR112012030689B1 publication Critical patent/BR112012030689B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

cristal de derivado de tienopirimidina. cristais são obtidos através de aquecimento de uma suspensão aquosa de ácido 2-(3,4-diclorobenzil)-5-metil-4-oxo-3,4-di-hidrotieno[2,3-d]pirimidino-6-carboxílico.novos cristais são obtidos através do ajuste da temperatura e/ou duração de aquecimento.
BR112012030689-8A 2010-05-31 2011-05-31 Cristal de derivado de tienopirimidina, medicamento, composição farmacêutica e método de produção e uso do cristal BR112012030689B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010-125362 2010-05-31
JP2010125362 2010-05-31
PCT/JP2011/062513 WO2011152411A1 (ja) 2010-05-31 2011-05-31 チエノピリミジン誘導体の結晶

Publications (2)

Publication Number Publication Date
BR112012030689A2 true BR112012030689A2 (pt) 2016-09-13
BR112012030689B1 BR112012030689B1 (pt) 2021-11-09

Family

ID=45066774

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012030689-8A BR112012030689B1 (pt) 2010-05-31 2011-05-31 Cristal de derivado de tienopirimidina, medicamento, composição farmacêutica e método de produção e uso do cristal

Country Status (15)

Country Link
US (2) US8748437B2 (pt)
EP (1) EP2594570B1 (pt)
JP (1) JP5744017B2 (pt)
KR (1) KR101721288B1 (pt)
CN (1) CN103038238B (pt)
AU (1) AU2011260861B2 (pt)
BR (1) BR112012030689B1 (pt)
CA (1) CA2801030C (pt)
EA (1) EA021987B1 (pt)
ES (1) ES2532110T3 (pt)
IL (1) IL223267A (pt)
MX (1) MX2012013924A (pt)
UA (1) UA111589C2 (pt)
WO (1) WO2011152411A1 (pt)
ZA (1) ZA201209488B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748437B2 (en) * 2010-05-31 2014-06-10 Aska Pharmaceutical Co., Ltd. Crystal of 2-(3,4 dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothien[2,3-D]pyrimidine-6-carboxylic acid
WO2018009899A1 (en) 2016-07-07 2018-01-11 Cardurion Pharmaceuticals, Llc Methods for treatment of heart failure
SG11202010161UA (en) * 2018-04-17 2020-11-27 Cardurion Pharmaceuticals Llc Meglumine salts of thienopyrimidines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4488867B2 (ja) 2004-11-05 2010-06-23 株式会社東芝 パターン形成方法
AU2006258461B2 (en) * 2005-06-14 2011-08-25 Aska Pharmaceutical Co., Ltd. Thienopyrimidine derivative
JPWO2008072778A1 (ja) 2006-12-13 2010-04-02 あすか製薬株式会社 尿路系疾患の処置剤
JP5047136B2 (ja) 2008-11-26 2012-10-10 サンデン株式会社 飲料用容器分別機
US8748437B2 (en) * 2010-05-31 2014-06-10 Aska Pharmaceutical Co., Ltd. Crystal of 2-(3,4 dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothien[2,3-D]pyrimidine-6-carboxylic acid

Also Published As

Publication number Publication date
CN103038238B (zh) 2016-05-04
KR20130112734A (ko) 2013-10-14
BR112012030689B1 (pt) 2021-11-09
IL223267A0 (en) 2013-02-03
JP5744017B2 (ja) 2015-07-01
US20140235655A1 (en) 2014-08-21
WO2011152411A1 (ja) 2011-12-08
EP2594570B1 (en) 2015-02-25
JPWO2011152411A1 (ja) 2013-08-01
UA111589C2 (uk) 2016-05-25
EP2594570A1 (en) 2013-05-22
ZA201209488B (en) 2014-02-26
US20130123279A1 (en) 2013-05-16
MX2012013924A (es) 2013-05-01
CA2801030A1 (en) 2011-12-08
ES2532110T3 (es) 2015-03-24
AU2011260861A1 (en) 2013-01-10
CA2801030C (en) 2018-11-27
KR101721288B1 (ko) 2017-03-29
IL223267A (en) 2016-10-31
EA201291289A1 (ru) 2013-05-30
CN103038238A (zh) 2013-04-10
US9006253B2 (en) 2015-04-14
EP2594570A4 (en) 2013-11-27
US8748437B2 (en) 2014-06-10
EA021987B1 (ru) 2015-10-30
AU2011260861B2 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
MX340490B (es) Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
AU2011288503A8 (en) 6-Cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
MX2012011779A (es) Pirimidinas modificadas en la posicion 5 y su uso.
BR112014032338A2 (pt) cristais de sal
SG11201502622VA (en) PYRROLO[3,2-<i>D</i>]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
EA201492165A1 (ru) Синтез пирроло[2,3-b]пиридинов
CO6620074A2 (es) Derivados de pirrolo [2, 3-b] piridinas para la inhibicion de quinasas raf
EA201890061A2 (ru) Производные пиразоло[1,5-a]пиридина и способы их применения
SG11201402197UA (en) [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
MX350112B (es) Derivados de furo[3,2-b]- y tieno[3,2-b]piridina como inhibidores de tbk1 e ikk.
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
IL232304A0 (en) [1,2,3]-Triazolo[4,5-d]pyrimidine derivatives are agonistic for cannabinoid receptor 2 agonists
AU2011325479A8 (en) 7-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyrazine derivatives
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
NZ608031A (en) Inhibitors of notum pectinacetylesterase and methods of their use
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
EP3190112A4 (en) Composition of (6s)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
IN2014MN02467A (pt)
EA201300997A1 (ru) ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ
HK1177207A1 (en) 5-oxo-5, 8-dihydropyrido [2, 3-d]pyrimidine derivatives as camkii kinases inhibitors for the treatment of cardiovascular diseases camkii 5--58-[23-d]
BR112012030689A2 (pt) cristal de derivado de tienopirimidina
BR112014000085A2 (pt) derivados de ácido carboxílico com um anel oxazolo[4,5-c]piridina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/05/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.